XTX Topco Ltd Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

XTX Topco Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,934 shares of the biopharmaceutical company’s stock, valued at approximately $405,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. William Blair Investment Management LLC boosted its stake in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after buying an additional 1,477,084 shares in the last quarter. Fiera Capital Corp grew its position in Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Amicus Therapeutics by 4.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after acquiring an additional 139,491 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after acquiring an additional 242,672 shares in the last quarter.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 30,401 shares of company stock worth $339,363 over the last 90 days. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Stock Down 7.8 %

NASDAQ:FOLD opened at $9.36 on Monday. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -27.53 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock’s fifty day moving average price is $10.52 and its two-hundred day moving average price is $10.62. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57.

Analyst Ratings Changes

FOLD has been the topic of several analyst reports. JPMorgan Chase & Co. upped their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 10th. Guggenheim lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.